We propose that the susceptibility to tyrosine kinase inhibitors of CCM3-deficient cells can be harnessed to kill the abnormal cells of these lesions and thus treat CCMs pharmacologically. This evidence concerns the gene PDCD10 and cerebrocostomandibular syndrome.